Nkcfo LLC Makes New Investment in Inotiv, Inc. (NASDAQ:NOTV)

Nkcfo LLC purchased a new position in shares of Inotiv, Inc. (NASDAQ:NOTV - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 115,000 shares of the company's stock, valued at approximately $476,000. Nkcfo LLC owned 0.44% of Inotiv as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vantage Point Financial LLC acquired a new position in shares of Inotiv in the 4th quarter valued at about $1,393,000. KPP Advisory Services LLC lifted its holdings in shares of Inotiv by 15.8% in the 4th quarter. KPP Advisory Services LLC now owns 275,267 shares of the company's stock valued at $1,140,000 after buying an additional 37,549 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Inotiv by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 250,895 shares of the company's stock valued at $427,000 after buying an additional 18,039 shares during the period. Thurston Springer Miller Herd & Titak Inc. lifted its holdings in shares of Inotiv by 612.5% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 127,257 shares of the company's stock valued at $527,000 after buying an additional 109,397 shares during the period. Finally, Calamos Advisors LLC acquired a new position in shares of Inotiv in the 4th quarter valued at about $275,000. Institutional investors and hedge funds own 18.17% of the company's stock.

Insider Buying and Selling

In related news, CEO Robert Jr. Leasure sold 22,700 shares of the company's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $4.15, for a total value of $94,205.00. Following the completion of the transaction, the chief executive officer now owns 1,030,209 shares of the company's stock, valued at approximately $4,275,367.35. This represents a 2.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Nigel Brown purchased 7,500 shares of Inotiv stock in a transaction that occurred on Tuesday, December 10th. The stock was acquired at an average cost of $4.26 per share, with a total value of $31,950.00. Following the acquisition, the director now directly owns 65,537 shares in the company, valued at $279,187.62. This trade represents a 12.92 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 71,029 shares of company stock valued at $314,248 and sold 26,872 shares valued at $112,854. 7.80% of the stock is currently owned by insiders.

Inotiv Stock Performance

Shares of NOTV stock traded up $0.06 on Wednesday, hitting $3.90. The company had a trading volume of 697,171 shares, compared to its average volume of 689,862. The firm has a market cap of $131.51 million, a P/E ratio of -0.85 and a beta of 3.58. The company has a 50-day moving average price of $4.37 and a 200-day moving average price of $2.93. The company has a quick ratio of 1.28, a current ratio of 1.57 and a debt-to-equity ratio of 2.31. Inotiv, Inc. has a twelve month low of $1.23 and a twelve month high of $11.42.

Inotiv (NASDAQ:NOTV - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.10). Inotiv had a negative net margin of 25.40% and a negative return on equity of 15.41%. As a group, equities research analysts predict that Inotiv, Inc. will post -0.79 earnings per share for the current fiscal year.

Inotiv Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.